- Home
- ICMB vs OTLK Comparison
ICMB vs OTLK Comparison
Compare ICMB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICMB
- OTLK
- Stock Information
- Founded
- ICMB 2012
- OTLK 2010
- Country
- ICMB United States
- OTLK United States
- Employees
- ICMB N/A
- OTLK N/A
- Industry
- ICMB Finance: Consumer Services
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICMB Finance
- OTLK Health Care
- Exchange
- ICMB Nasdaq
- OTLK Nasdaq
- Market Cap
- ICMB 40.6M
- OTLK 48.3M
- IPO Year
- ICMB N/A
- OTLK 2016
- Fundamental
- Price
- ICMB $2.72
- OTLK $2.34
- Analyst Decision
- ICMB
- OTLK Strong Buy
- Analyst Count
- ICMB 0
- OTLK 5
- Target Price
- ICMB N/A
- OTLK $9.60
- AVG Volume (30 Days)
- ICMB 28.0K
- OTLK 1.1M
- Earning Date
- ICMB 08-12-2025
- OTLK 08-14-2025
- Dividend Yield
- ICMB 17.65%
- OTLK N/A
- EPS Growth
- ICMB N/A
- OTLK N/A
- EPS
- ICMB 0.93
- OTLK N/A
- Revenue
- ICMB $20,422,069.00
- OTLK $1,505,322.00
- Revenue This Year
- ICMB N/A
- OTLK N/A
- Revenue Next Year
- ICMB N/A
- OTLK $407.74
- P/E Ratio
- ICMB $2.93
- OTLK N/A
- Revenue Growth
- ICMB N/A
- OTLK N/A
- 52 Week Low
- ICMB $2.46
- OTLK $0.87
- 52 Week High
- ICMB $3.47
- OTLK $8.32
- Technical
- Relative Strength Index (RSI)
- ICMB 43.65
- OTLK 63.83
- Support Level
- ICMB $2.60
- OTLK $1.95
- Resistance Level
- ICMB $2.71
- OTLK $2.14
- Average True Range (ATR)
- ICMB 0.09
- OTLK 0.17
- MACD
- ICMB -0.01
- OTLK 0.03
- Stochastic Oscillator
- ICMB 54.05
- OTLK 77.62
About ICMB Investcorp Credit Management BDC Inc.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.